AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Diogo Mota
Public Documents
3
Real-world evidence on the risk of cancer with anti-IL-5 and anti-IL-4Ra biologicals
Diogo Mota
and 2 more
August 01, 2022
Title: Real-world evidence on the risk of cancer with anti-IL-5 and anti-IL-4Ra biologicalsAuthors : Diogo Mota1; Tiago Azenha Rama1, 2, 3, 4; André Moreira1, 2, 3, 4
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's Vig...
Diogo Mota
and 3 more
June 29, 2021
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database
Potential cancer risk with omalizumab: a disproportionality analysis of the WHO’s Vig...
Diogo Mota
and 3 more
April 13, 2021
Potential cancer risk with omalizumab: a disproportionality analysis
